Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

Some would say Eli Lilly just had its Novo Nordisk moment. Analysts mostly agree that the selloff in Lilly shares after the ...

Wilson Encourages Investors Who Suffered Losses In Novo To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Novo between May 7, 2025, to July 28, 2025 and would ...

Weight-loss drugs significantly improve health, though they’re also tied to increased spending on other medical care that’s ...

Prime Minister Benjamin Netanyahu’s security cabinet today approved his proposal for a gradual military takeover of Gaza, his ...

Novo Nordisk filed 14 new lawsuits against compounders claiming to contain semaglutide, the component of its Ozempic and ...

The drugmaker is a large and consistent client for Covington. The law firm has represented Novo Nordisk in several dozen ...

Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...

Otte took on the title in February, the culmination of nearly 25 years spent with the Danish drugmaker. As of his departure ...

GLP-1 receptor agonists are associated with risk reductions for dozens of diseases and conditions in addition to rapid weight loss; however, they can also bring unwelcome side effects, including ...

Users of weight loss drugs such as Wegovy and Mounjaro, along with those who use type 2 diabetes drug Ozempic for weight loss ...